• Publications
  • Influence
Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia.
TLDR
This study showed that pneumonia-causing Legionella species and serogroup distribution was comparable to that reported in former surveillances and assessed in vitro activity of antibiotics against these isolates and showed that quinolones and macrolides have potent anti-Legionella activity. Expand
Validation of a diagnostic score model for the prediction of Legionella pneumophila pneumonia.
TLDR
This validated Legionella Score was shown to have good diagnostic ability with a positive likelihood of 3.7 and a negative likelihood of 0.10 and to have sensitivity of 93% and specificity of 75%. Expand
[Study on the safety and efficacy of sitafloxacin--results of the use-results survey].
TLDR
This use-results survey confirmed that STFX is a useful antibacterial agent with no serious problems in its safety profile and efficacy rates of over 90% against all infections. Expand
Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy.
TLDR
The results suggested that the previously reported clinical scoring systems to predict Legionnella pneumonia are not useful, but 6 simple diagnostic score accurately ruled out Legionnelle pneumonia, which may help to optimize initial empiric therapy. Expand
Diagnostic predictors of Legionella pneumonia in Japan.
In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan.
TLDR
Quinolones and macrolides had potent antimicrobial activity against both extracellular and intracellular Legionella species, and the possible efficacy of these drugs in treatment of Legionella infections is suggested. Expand
Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism - An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan).
TLDR
Safety and effectiveness profiles of edoxaban in patients receiving the low dose (30 mg/day), generally administered to patients with high bleeding risk, were similar to those of the standard dose (60 mg/ day). Expand
Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative
TLDR
In this retrospective real-world evaluation of IHD patients with NVAF and PCI, DOAC-treated patients had a lower risk of developing clinically relevant bleeding compared with the VKA group. Expand
Safety and Effectiveness of Edoxaban in Japanese Venous Thromboembolism Patients ― Final Analysis of One-Year Follow-up Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan) ―
TLDR
The safety and effectiveness profiles of edoxaban in patients receiving the appropriate low dose (30 mg/day), generally used in patients with high bleeding risk, were similar to those for the appropriate standard dose (60 mg/ day). Expand
[Efficacy and safety of sitafloxacin in patients with urinary tract infections].
TLDR
It is suggested that STFX is a useful antibacterial agent with an efficacy rate of 91.4% against urinary tract infections, with a minimum efficacy rates of 87.2% (against complicated cystitis), and has no serious problems in its safety profile. Expand
...
1
2
...